After treatment with IL-17 antibody, the expression of ACE2 was down-regulated, indicating that IL-17 antibody may reduce the risk of virus infection by reducing the number of cells interacting with SARS-CoV-2 (Xu et al., 2021). This evidence concerns the gene IL17A and viral infectious disease.